Froncort.AI, an Indian healthcare AI startup focused on disease detection, has raised $2.3 million from Google.org to enhance and expand its AI-driven disease surveillance platform across multiple infectious diseases.
- Froncort.AI develops AI tools for infectious disease detection and surveillance.
- Google.org investment includes $2.3M funding, cloud credits, and expert support.
- Mobile platform mAI-NETRA to be open-sourced for government adoption.
What happened
Froncort.AI has received $2.3 million in fresh funding from Google.org, Google's philanthropic division, along with $200,000 in Google Cloud credits and pro bono AI expertise to scale its existing AI-NETRA disease surveillance platform. Founded in 2024 by Dr. Ujjwal Rao, the startup uses AI combined with satellite data and official health statistics to detect infectious disease hotspots.
With the new funding, Froncort.AI will create mAI-NETRA, a mobile solution designed for frontline health workers to navigate and efficiently target high-risk households. The startup’s AI platform has demonstrated effectiveness in a study with Maharashtra’s TB program by reducing the number of people screened while maintaining detection rates and lowering costs per confirmed case.
Why it matters
This investment marks a significant endorsement of AI technologies in strengthening India’s public health response to infectious diseases. By enabling earlier, targeted detection and minimizing the workload of frontline workers, Froncort.AI’s platform supports efficient resource use and potentially reduces disease burden.
The open-source release of mAI-NETRA will allow governments to customize and deploy the technology widely, supporting India's broader national strategy to integrate AI across key public health initiatives. This aligns with India’s increased focus on AI-driven healthcare, backed by substantial growth in AI funding and government-led infrastructural reforms.
What to watch next
Key next steps include the rollout of mAI-NETRA to cover six infectious diseases—TB, leprosy, malaria, dengue, cholera, and leptospirosis—across diverse regions. Monitoring adoption rates and documented public health outcomes will indicate the platform’s broader impact and scalability.
Additionally, observing how government health programs incorporate this technology and whether other AI startups follow suit will be important. Continued support and investment in AI for healthcare in India are likely, given the promising initial results and strategic national initiatives promoting AI integration.